TY  - CONF

T1  - A phase IIa study of amlitelimab, a novel nondepleting anti-OX40Ligand mAb in patients with moderate to severe atopic dermatitis

JO  - BRITISH JOURNAL OF DERMATOLOGY

PY  - 2022/01/01

AU  - Weidinger S

AU  - Cork M

AU  - Reich A

AU  - Beiber T

AU  - Gilbert S

AU  - Brennan N

AU  - Wilson R

AU  - Quaratino S

AU  - Porter-Brown B

ED  - 

VL  - 187

IS  - 3

SP  - E96

EP  - E96

Y2  - 2024/12/22

ER  -